Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

orphan medicines

Together Caring for Rare Disease

Medscape Education and Medics4RareDisease are partnering on a Rare Disease Day awareness campaign. The campaign will form part of a series of short programs produced by ITN in collaboration with Genetic Alliance...

Medscape Education Global

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Research Partnership

- PMLiVE

Medscape Education and Medics4RareDisease Uncover the Education Gaps in Their Compelling Rare Disease Day Campaign

Medscape Education and Medics4RareDisease are partnering on a Rare Disease Day awareness campaign. The campaign will form part of a series of short programs produced by ITN in collaboration with Genetic Alliance...

Medscape Education Global

- PMLiVE

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%

Early pipeline planning depicted with a pipe and data-oriented imagery.

Why it’s time to apply a payer lens to your early pipeline planning

Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...

Avalere Health

- PMLiVE

Sarepta to assess imlifidase as pre-treatment to Duchenne muscular dystrophy gene therapy

The company submitted a Biologics License Application to the FDA for SRP-9001 in September

Cell and gene therapies as depicted via a DNA strand

The fast-paced future of cell and gene therapies

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

Avalere Health

- PMLiVE

FDA receives Santhera and ReveraGen’s application for Duchenne muscular dystrophy treatment

The submission includes positive data from the pivotal phase 2b and four open-label studies

Patient Centric Approaches for Rare and Ultra-Rare Diseases

Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale....

Impetus Digital

Profile pics of Priti and Tijana

Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...

Genesis Research Group

- PMLiVE

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

Avalere Health

- PMLiVE

Report: Reinventing product and portfolio value for the biopharmaceutical industry

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...

Avalere Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links